May 15, 2008
Strength and innovation of Novartis Oncology products and pipeline with potential to improve patient treatment demonstrated by more than 170 abstracts at ASCO annual meeting
- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer
- Plenary session to highlight impact of ZometaŽ, the leading IV bisphosphonate, on relapse rate of patients with early-stage breast cancer
- Four oral sessions to feature RAD001, first oral once-daily continuous inhibitor of mTOR, including first results of RECORD-1 study in renal cell carcinoma
- Updated Phase II results with TasignaŽ in Philadelphia chromosome-positive chronic myeloid leukemia to be presented
April 11, 2008
ASA404, a novel cancer agent, begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death
- With launch of Phase III ATTRACT-1 trial in non-small cell lung cancer, Novartis Oncology assumes responsibility for development of ASA404 from Antisoma
- Novel mechanism of action of ASA404 disrupts existing blood supply to tumors
- Tumor-Vascular Disrupting Agent is one of six Novartis Oncology compounds in late-stage development for various solid tumors and blood cancers
March 10, 2008
Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen
- Femara only member of aromatase inhibitor class with data demonstrating this potential benefit, as published in Journal of Clinical Oncology
- Half of all breast cancer recurrences occur five or more years after diagnosis
- Separate analysis published in Annals of Oncology affirms significant advantages of Femara when taken after standard tamoxifen therapy
February 28, 2008
Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy
- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus
- Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR
- Results of RECORD-1 trial address unmet medical need in renal cell cancer with worldwide regulatory filings planned for second half of 2008
- Complete results to be submitted as late-breaking abstract for presentation at the American Society of Clinical Oncology meeting
